These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 24310424)

  • 1. The pharmacokinetics and pharmacodynamics of iron preparations.
    Geisser P; Burckhardt S
    Pharmaceutics; 2011 Jan; 3(1):12-33. PubMed ID: 24310424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of trivalent iron in oral iron preparations. Therapeutic efficacy and iron absorption from simple ferric compounds and high- or low-molecular weight ferric hydroxide-carbohydrate complexes.
    Heinrich HC
    Arzneimittelforschung; 1975 Mar; 25(3):420-6. PubMed ID: 1174047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron pharmacokinetics after administration of ferric-hydroxide-polymaltose complex in rats.
    Geisser P; Müller A
    Arzneimittelforschung; 1984; 34(11):1560-9. PubMed ID: 6543131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
    Lyseng-Williamson KA; Keating GM
    Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of iron salts and ferric hydroxide-carbohydrate complexes.
    Geisser P; Müller A
    Arzneimittelforschung; 1987 Jan; 37(1A):100-4. PubMed ID: 3566862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF-PH inhibitor for the treatment of renal anaemia.
    Lentini S; Kaiser A; Kapsa S; Matsuno K; van der Mey D
    Eur J Clin Pharmacol; 2020 Feb; 76(2):185-197. PubMed ID: 31919558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics.
    Funk F; Flühmann B; Barton AE
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
    Qunibi WY
    Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose.
    Funk F; Ryle P; Canclini C; Neiser S; Geisser P
    Arzneimittelforschung; 2010; 60(6a):345-53. PubMed ID: 20648926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants.
    Pollak A; Hayde M; Hayn M; Herkner K; Lombard KA; Lubec G; Weninger M; Widness JA
    Pediatrics; 2001 Jan; 107(1):78-85. PubMed ID: 11134438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers.
    Danielson BG; Salmonson T; Derendorf H; Geisser P
    Arzneimittelforschung; 1996 Jun; 46(6):615-21. PubMed ID: 8767353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress.
    Koskenkorva-Frank TS; Weiss G; Koppenol WH; Burckhardt S
    Free Radic Biol Med; 2013 Dec; 65():1174-1194. PubMed ID: 24036104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P; Rumyantsev V
    Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose intravenously administered iron versus orally administered iron in blood donors with iron deficiency: study protocol for a randomised, controlled trial.
    Macher S; Drexler C; Lindenau I; Sareban N; Schlenke P; Amrein K
    Trials; 2016 Oct; 17(1):527. PubMed ID: 27793204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin.
    Meyer MP; Haworth C; Meyer JH; Commerford A
    J Pediatr; 1996 Aug; 129(2):258-63. PubMed ID: 8765624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Importance of the different i.v. iron generations for everyday medical practice].
    Biggar P; Hahn KM
    MMW Fortschr Med; 2013 Mar; 155 Suppl 1():18-24. PubMed ID: 23678667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice].
    Rottembourg J; Rostoker G
    Nephrol Ther; 2015 Dec; 11(7):531-42. PubMed ID: 26498106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Food interaction of oral uptake of iron / a clinical trial using 59Fe.
    Lundqvist H; Sjöberg F
    Arzneimittelforschung; 2007; 57(6A):401-16. PubMed ID: 17691590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A; Bhandari S
    Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.